Factor XIII subunit A (FXIII-A) in the skin: applications in diagnosis and treatment by Paragh, Lilla & Töröcsik, Dániel
Factor XIII subunit A (FXIII-A) in the skin – applications in diagnosis and 
treatment  
 
Lilla Paragh and Daniel Törőcsik 
 
 
 
Lilla Paragh and Daniel Törőcsik1  
 
Department of Dermatology, Faculty of Medicine, University of Debrecen, 
Debrecen, Hungary 
1Corresponding author 
 
Email: dtorocsik@gmail.com 
 
 
Abstract 
 
The role of factor XIII subunit A (FXIII-A) is not restricted to hemostasis. FXIII-
A is also present intracellularly in several human cells and serves as a 
diagnostic marker in a wide range of dermatological diseases from 
inflammatory conditions to malignancies. In this review, we provide a guide on 
the still controversial interpretation of dermal cell types expressing FXIII-A and 
assessed the previously described mechanisms behind their accumulation 
under physiological and pathological conditions of the human skin. We 
summarize the intracellular functions of FXIII-A as well as its possible sources 
in the extracellular space of the dermis with a focus on its relevance to skin 
homeostasis and disease pathogenesis. Finally, the potential role of FXIII-A in 
wound healing, as a field with long-term therapeutic implications, is also 
discussed.  
 
 
 
  
  
 
Introduction 
 
Factor XIII (FXIII), fibrin stabilizing factor, is an enzyme consisting of 
two subunits: an A (FXIII-A) and a B subunit (FXIII-B) that can form a 
tetrameric complex in the plasma (pFXIII-A) with two of each subunit (FXIII-
A2B2). As a member of the transglutaminase family, FXIII crosslinks fibrin 
residues to produce the mature clot in blood coagulation [1]. In addition to 
being a pivotal member of the coagulation cascade, FXIII-A is also found 
intracellularly (cFXIII-A) in various cells all around the body. Besides 
megakaryocytes and platelets, monocytes [2], macrophages [3], dendritic 
cells (DCs) [4], fibroblasts [5], mast cells [6] and sebocytes [7], all with an 
important role in the homeostasis of the skin, have been listed as FXIII-A-
producing cells. Thus, FXIII-A is of interest in not only the fields of hemostasis 
but also cellular expression and skin biology. Therefore in this review, besides 
giving a general overview on FXIII-A production and its presence in the 
intracellular and extracellular space, we also aim to summarize our current 
knowledge on the role of FXIII-A in the (patho)physiology of the skin and 
discuss its possible cutaneous therapeutic applications. (Abbreviations used 
in relation to FXIII are shown in Table 1). 
 
 
FXIII-A in the circulation 
 
FXIII, as mentioned before, is a member of the transglutaminase 
family. In the plasma, FXIII is present as a tetramer where FXIII-A is the 
catalytic enzyme and FXIII-B is a glycoprotein responsible for inhibiting FXIII-
A upon binding to it. Only approximately 1% of FXIII-A exists in a free form in 
the plasma. FXIII-A upon activation crosslinks the γ-glutamyl and ε-lysyl 
residues of connected polymerized fibrin chains to produce the mature clot 
during hemostasis [1]. For more details regarding their interaction and role in 
blood coagulation, we refer to the excellent reviews [8-10]. 
While FXIII-B is exclusively produced by the liver [11] and is only 
present in the circulation, FXIII-A can also be found in the blood, extracellular 
space and in the cytoplasm of various cells. Therefore, we are focusing our 
review on the role of FXIII-A. pFXIII-A has long been thought to originate in 
bone marrow, mainly produced by megakaryocytes and platelets. However, 
the findings of Poon et al. suggested that other cells might also contribute to 
pFXIII levels. During bone marrow ablation, they noted only a 25% reduction 
in pFXIII levels in contrast to a 90% reduction in platelet count. The reduction 
of pFXIII levels was also less than expected in thrombocytopenic patients, 
further supporting the presence of a non-thrombopoietic source of pFXIII [1, 2, 
12]. Studies by Griffin at al, using a model where mice floxed in coding exon7 
of the FXIII-A gene (F13A1) were crossed with mice transgenic for Pf4-Cre-
recombinase (thrombopoietic deletion) or Cd11b-Cre-recombinase (myeloid 
deletion), raised the possibility that a unique Pf4-dependent progenitor cell is 
the major source of the plasma pool, which was independent of 
thrombopoietin receptor. While in F13A1fl/fl-Pf4-cre mice FXIII-A plasma 
activity was decreased by 85% and absent in platelets, in F13A1/fl-CD11b-cre 
mice plasma activity decreased by 40%. Interestingly, F13A1 mRNA levels 
also decreased in the aorta (91.6%) and heart (99.2%) of F13A1fl/fl-Pf4-cre 
mice, but showed no reduction in the heart and a 54.6% reduction in the aorta 
tissue samples of F13A1fl/fl-CD11b-cre mice [13]. 
 
Extracellular FXIII-A 
 
Because FXIII-A lacks a signal sequence for secretion, for a long time, 
the only possible explanation was that ecFXIII-A was either from the 
circulation or originated from dying cells. These were supported by in vitro 
findings that FXIII-A could not be detected in the culture medium when it was 
expressed in baby hamster kidney cells [10].	   However, Cordell et al 
suggested nonclassical secretion by showing that FXIII-A in macrophages 
was associated with podosomes and was present in intracellular vesicles 
associated with Golgi matrix protein-130 (GM-130), which is implicated in the 
delivery of proteins to the plasma membrane [14]. Interestingly, under specific 
conditions, FXIII-A can also appear on the cell surface where it could exert its 
transglutaminase activity and play a role in modulating cell adhesion [15]. 
Based on these findings, FXIII-A-positive macrophages were 
implicated in the elevation of ecFXIII levels both in the bronchoalveolar lavage 
fluid of patients with asthma [16] and in tissue samples of patients with 
chronic rhinosinusitis with nasal polyps [17]. Considering the known substrate 
profile of FXIII-A, such as fibronectin, vitronectin, osteopontin, 
thrombospondin and certain adhesive glycoprotein components of the 
extracellular matrix (ECM), which will be discussed later in this review, the 
alterations in the ecFXIII-A levels might contribute to tissue repair in these 
diseases. Although, the correlation between the levels of ecFXIII-A and the 
increased number of FXIII-A-positive macrophages corroborated that cFXIII-A 
could be a potent contributor to ecFXIII-A levels [15], questions as to which of 
the FXIII-A producing cell types could indeed contribute to ecFXIII-A and the 
stimuli behind its possible secretion are yet to be answered. Based on these 
findings, future studies are also needed in the filed of dermatology to examine 
the correlation of ecFXIII-A with FXIII-A-positive cells within various skin 
lesions. While using mouse models with selective ablation of the FXIII-A-
positive skin-resident macrophages, their contribution to ecFXIII-A (and 
perhaps to pFXIII-A) levels could be assessed as well. 
 
 
Intracellular FXIII-A  
 
Whereas in early embryonic life, the cells positive for cFXIII-A are the 
mesenchymal histiocytes and hepatocytes [18], in adult life, in addition to 
monocytes and tissue macrophages [3], cFXIII-A was detected also in DCs 
[4], fibroblasts [5], sebocytes [7] and mast cells of the skin and recently in the 
subcutaneous preadipocytes [19]. Although it is outside the scope of this 
review, osteoblasts, chondrocytes [20, 21], and cornea cells [22] should also 
be listed here as FXIII-A-producing cells [23, 24]. Confirming that the 
intracellular Ca2+ concentration is sufficient for its activation within the cell as 
shown in platelets and monocytes [8], cFXIII-A was also suggested to play a 
role in various intracellular (intracytoplasmic and intranuclear) processes [25].  
 
Macrophages 
  
Being the first cell type in which cFXIII-A was detected more than 30 
years ago [26], the circulating blood monocytes/macrophages provide an 
excellent model for the examination of the possible roles of cFXIII-A. It was 
shown that cFXIII-A is present from a very early stage of monocyte 
differentiation (monoblasts in the bone marrow) [27, 28] to the macrophages 
of connective tissue and serous cavities [29]. Based on these findings, FXIII-A 
became interpreted as a marker protein of the cell line. Actin and myosin [30], 
the two major elements of the cell cytoskeletal locomotory system, were the 
first identified intracellular substrates, followed by vinculin [31], the small heat 
shock protein HSP27 [32] and thymosin beta4 [33]. All these molecules have 
a significant role in cytoskeletal remodeling [8]. cFXIII was also suggested to 
participate in the phagocytosis of certain particles. Fcg and complement 
receptor-mediated uptake of sensitized erythrocytes and complement-coated 
yeast particles were greatly diminished in monocytes of FXIII-deficient 
patients. The phagocytic functions of cultured monocytes/macrophages 
showed changes alongside FXIII-A mRNA expression and protein synthesis 
[34]. In addition, cFXIII-A can also induce the activation and mobilization of 
monocytes from the splenic reservoir in response to angiotensin II binding its 
receptor (AT1), which can activate cFXIII-A that in return dimerizes AT1 [35].  
Interestingly, FXIII-A was also shown to translocate to the nucleus of 
differentiating macrophages where it may also exert its enzymatic activity. It 
still needs to be elucidated if this is behind the altered gene expression profile 
of FXIII-A-deficient macrophages or a cytoplasmic activity targeting 
unidentified proteins. The significant changes in genes involved in wounding, 
immune processes and ECM formation show that cFXIII-A is involved in a 
wide range of cellular processes, including participating in gene expression 
regulation of the key functions of macrophages, such as phagocytosis [15]. 
However, we also showed that the presence of cFXIII-A was not ubiquitous in 
macrophages but marked a specific activated status, the so-called alternative 
activation. Such activated macrophages are characteristic to the healthy skin 
and dominant in pathological conditions where inflammation is not related to 
infection. These are conditions, such as wounding or tumor development, that 
display ECM formation and where cFXIII-A expression could have a 
significant diagnostic value that we will introduce in more detail later in the 
dermatopathology section. The key cytokine driving macrophages toward the 
alternative polarization is IL-4. IL-4 was shown to be the strongest inducer of 
FXIII-A gene expression and protein levels within macrophages so far [15]. 
On the contrary, in infectious lesions, such as tuberculosis, TNFα and IFNγ 
are the cytokines behind the classical activation of macrophages and in 
parallel inhibit the expression of cFXIII-A [34]. This interesting finding could 
explain, at least partially, why FXIII-A-deficient patients have no reported 
increased susceptibility to infectious diseases.  
 
Dendritic cells 
 
In addition to macrophages, FXIII-A was identified in a great variety of 
cell types. However, the question of antibody specificity was put forward in 
many cases. The validity of the term “FXIII-A dendrocytes”, which has been 
widely accepted and is still used [36], is one of the prime examples of such 
debates. A detailed characterization of dermal FXIII-A-positive cells by Zaba 
et al highlighted that FXIII-A could be detected only in macrophages. Cells 
capable of antigen presentation in the skin, which is the hallmark of dendritic 
cells (DCs), lacked FXIII-A [37]. A possible explanation for the discrepancies 
between ex vivo and in vitro findings could be that IL-4 in combination with 
GM-CSF is a widely used but also challenged [38] cytokine combination for in 
vitro DC differentiation. In such models, FXIII-A-deficient DCs showed a 
reduced chemotactic response to CCL19 and impaired cell motility [39]. 
Based on these data, further studies are needed to determine if the 
presence of cFXIII-A is just a “side-product” in in vitro differentiated DCs, due 
to its previously described induction by IL-4, or if there are certain DC subsets 
expressing FXIII-A also under in vivo conditions.  
 
Mast cells 
 
Recently, interest in mast cells as FXIII-A-producing cells [6] that could 
contribute to ecFXIII-A and perhaps to pFXIII levels has grown. Using 
immunogold labeling and electron microscopy, the double staining for FXIII-A 
and tryptase showed that in sections of drug-induced acute urticaria, the two 
proteins co-localized within the granules of mast cells. Interestingly, the 
granules were also detected in dermal DCs and in endothelial cells of post-
capillary venules, suggesting a mast cell - dermal dendrocyte/endothelial cell 
interaction in urticaria [40, 41]. Additionally, after IgE mediated activation of 
bone marrow–derived cultured mast cells (BMCMCs), cFXIII-A was found to 
be one of the most abundant proteins in the proteome. However, in mast cell–
deficient mice, pFXIII and activity levels were increased in correlation with 
reduced bleeding times. The root of these changes was that the human 
chymase and mouse mast cell protease-4 (the mouse homologue of human 
chymase) could downregulate FXIII-A via proteolytic degradation. Thus, 
deficiency of the chymase led to increased FXIII-A amounts and activity, as 
well as reduced bleeding times in homeostatic conditions and during sepsis. 
Mast cells are ever-evolving cell types not just in urticaria but also in other 
dermatological conditions such as psoriasis. It is of crucial importance to 
further confirm the role of mast cell–derived FXIII-A in human disease settings 
[6]. 
 
Fibroblasts, sebocytes and keratinocytes 
 
FXIII-A positivity of fibroblasts [5] keratinocytes and sebocytes turned 
out to be dependent on the applied antibody. A recent study found that the 
clone AC-1A1 mouse monoclonal antibody for FXIII-A was a useful tool for 
staining sebocytes with increased proliferative activity. It suggested that in the 
future, this antibody can be used in the diagnosis of sebocyte-related 
malignancies [7]. Using the same antibody, keratinocytes were also positive 
showing a correlation with their maturation. However, using different 
antibodies for FXIII-A, we did not detect FXIII-A-positive sebocytes or 
keratinocytes in the examined specimens, which is in line with other authors. 
 
 
 
(Pre)adipocytes 
 
FXIII-A was also shown to negatively regulate adipogenesis in mouse 
white adipose tissue and in differentiating 3T3-L1 preadipocytes. FXIII-A on 
the surface of the studied preadipocytes contributed to cell-matrix interactions 
by promoting the assembly of fibronectin from plasma into the preadipocyte 
extracellular matrix. Modulation of cytoskeletal dynamics induced the 
proliferation of the cells and at the same time inhibited their differentiation into 
lipid-accumulating mature adipocytes. FXIII-A, via the same pathway, might 
also be crucial in the transformation of embryonic fibroblasts into adipocytes 
[19]. More and more evidence supports that subcutaneous adipose tissue is in 
direct communication with the dermis through altering local inflammation and 
defense mechanisms against pathogens [42]. It is of interest to address 
subcutaneous adipose tissue and its FXIII-A levels in various inflammatory 
skin lesions.  	  
Application of FXIII-A in dermatopathology 	  
Shortly after the discovery that cFXIII-A is expressed in macrophages 
of various origin throughout the body [26, 29, 43], its detection has been 
implicated in dermatological diagnosis and a heterogenic population of FXIII-
A-positive dermal dendritic cells was also described.[36, 44]  
Ceiro et al. detected “FXIII-A dendrocytes” both in the neonatal foreskin 
and normal adult skin mainly in the upper dermis and in the papillary dermis 
surrounding vessels. Due to the limits of the available functional testing of 
such cells both in vivo and ex vivo at that time, the term “FXIII-A dendrocyte” 
was derived from the spindle shape appearance of such cells rather than from 
their potential to present antigens. As we have previously detailed, with the 
improvement of available tools and in our knowledge of the differences 
between macrophages and DCs, it is more likely that FXIII-A positivity 
indicates alternative activation of macrophages [34, 37].  
In the next section, we aim to systematically describe diseases with 
FXIII-A-positive cells, using the terms for the identified cell types according to 
original publications. 
 
 
FXIII-A in granulomatous diseases 
Granulomas are characteristic to diseases in which the immune system 
is incapable of eliminating the antigen that can be of pathogen or of 
noninfectious origin such as lipids or foreign bodies. Although T cells and DCs 
are also involved in granuloma formation, the key cells leading to the well-
recognized histological changes are the macrophages.  
Our findings that FXIII-A marks the alternative activation pathway in 
macrophages is best reflected in diseases of granuloma annulare (GA) and 
necrobiosis lipoidica (NL), which are the prime examples of noninfectious, 
nonmalignant inflammatory skin diseases with granuloma formation. Although 
the activating stimuli behind the symptoms are not known, (connective tissue 
disorder, impaired local circulation, lack of anti-inflammatory signaling 
affecting the macrophages), there is a remarkable change in ECM 
remodeling. Our results demonstrated that the macrophages in both diseases, 
expressed both FXIII-A and CD206 (also a widely-accepted marker for 
detecting alternatively activated macrophages). Moreover, we also found that 
FXIII-A-positive cells formed distinct populations from both CD11c and CD1a 
expressing cells in GA as well as in NL [25], which markers were convincingly 
shown to detect DCs in the healthy skin [37]. Altogether, besides 
demonstrating that FXIII-A is a useful tool to mark alternatively activated 
macrophages also in pathological conditions such as GA and NL we also 
proposed to integrate the classification by Zaba et al. for macrophages and 
DCs into dermatopathology [25]. Importantly, further characterization of FXIII-
A-positive cells revealed, that the cells expressing FXIII-A also expressed the 
macrophage marker CD163, whereas only 60% co-expressed CD68, a 
marker that has been also widely used to detect macrophages. To explain 
these findings, it should be kept in mind that the skin is a dynamic system and 
therefore it would be an oversimplification to search for such polarized 
conditions as described in in vitro conditions in any given disease. Therefore 
these findings further highlight the importance of multiple labeling in cases 
where the characterization of the macrophage populations is essential in 
setting up a diagnosis. To allow further conclusions and new perspectives in 
its dermatopathological application, we emphasize the importance of using 
multiple immunohistochemical markers in the description of FXIII-A-positive 
cells. We have collected the markers that have been used so far in 
combination with FXIII-A in Table 2.  
As we introduced previously, on the other extreme of macrophage 
polarization is classical activation, which marks the presence of TNFα and/or 
IFNγ in the inflammatory environment. These cytokines are typical in 
pathogen-associated lesions such as tuberculosis granulomas caused by 
Mycobacteria but are also the key cytokines in sarcoidosis, a disease lacking 
any pathogen. Supporting our previously detailed in vitro findings, 
macrophages were FXIII-A negative in the inflammatory foci of both 
tuberculosis and leprosy, just as in sarcoidosis [45]. Interestingly, FXIII-A-
positive macrophages could still be found near the granulomas. This finding 
can be explained with the possible commitment of FXIII-A-positive resident 
macrophages to keep their FXIII-A expression, just as the ongoing tissue 
damage and reorganization might be an inducer for a subset of alternatively 
activated macrophages.  
It is important to emphasize that FXIII-A is also not correlated with the 
presence of a pathogen but with the microinflammatory environment. This 
finding is best reflected in chronic suppurative granulomatous mycoses. An 
increased number of hypertrophied FXIII-A-positive DCs with prominent 
dendrites was seen in paracoccidiomycosis [46] and in chromoblastomycosis, 
of which some were colocalized with the pathogen itself [47].  
In systemic histiocytic disorders, such as juvenile xanthogranuloma, 
xanthoma disseminatum, Erdheim-Chester disease and dendrocytomas, 
FXIII-A, along with other markers (e.g., S100, CD1a, CD68, fascin, CD207, 
CD35), is also used as a key diagnostic tool [48-50]. As reported previously, 
FXIII was co-expressed with CD68 in these diseases, allowing the conclusion 
that these cells are mostly phagocytes. However, the mechanisms behind its 
induction and the question as to whether FXIII-A has any role in these 
diseases remain unanswered.  
 
FXIII-A in neoplasms 
The expression of FXIII has also been studied in solid tumors, but the 
specificity of the antibodies used for FXIII-A and the lack of multiple co-
labeling to characterize the FXIII-A-expressing cells might also lead to 
misinterpretation of these results with time. 
Kaposi’s sarcoma is a lymphangioproliferative disease caused by an 
HHV8 infection; it has 4 clinical presentations: classic, African endemic, 
iatrogenic immunosuppression related and acquired immunodeficiency 
syndrome (AIDS). It was one of the first malignancies where FXIII-A became 
introduced as a diagnostic tool. The spindle-shaped FXIII-A-positive DCs 
around the small blood vessels suggested that they might play a role in the 
angioproliferative process [51]. Confirming the importance of these findings, 
FXIII-A is still a widely-used marker in the diagnosis of Kaposi’s sarcoma, but 
without any association to AIDS. 
Another disease in which FXIII-A has stood the test of time and is used 
in the diagnosis is dermatofibroma (DF) where the spindle-shaped cells are 
FXIII-A positive but negative for CD34, in contrast to dermatofibrosarcoma 
protuberans (DFSP) where the cells are negative for FXIII-A and CD34 
positive [52, 53]. The CD34 and FXIII-A-positive (CDa1-) marker combination 
has also been described in medallion-like dermal dendrocyte hamartomas, 
which is a benign congenital dermal lesion [54].   
FXIII-A was also suggested to be a useful tool in differentiating 
between schwannomas neurofibromas and neurotized melanocytic nevi, 
which are common benign cutaneous neoplasms. In contrast to S100 protein, 
which was found to be expressed by tumor cells in all three diseases, FXIII-A 
was only found in neurofibromas (30-70% of cells within the tumors were 
positive for FXIII-A) [55]. However, whether the same cells were expressing 
S100 and FXIII-A proteins or FXIII-A positive cells were distinct ones 
infiltrating the tumor were not confirmed. 
The expression of FXIII was examined in patients with tuberous 
sclerosis as well, where it was present in the stromal cells of the skin lesion 
[56]. It was suggested that cFXIII-A also takes part in fibrous tumor formation 
as an inducer of growth, such as a growth factor, based on its expression in 
fibrokeratomas, angiofibromas (adenoma sebaceum of Pringle), and oral 
fibrous hyperplasia [5].  
A study of patients with oral squamous cell carcinoma suggested that 
the Leu allele of the FXIIIVal34Leu polymorphism, which decreases FXIII-A 
activity, is associated with an increased risk of squamous cell carcinoma, 
although without the increase in disease progression. Possibly both of these 
findings are due to a less porous fibrin network of thinner fibers that may 
facilitate tumor stroma formation and tumor cell proliferation but harbor tumor 
cells less effectively during metastasis formation [57]. In addition to this 
finding, in basal cell carcinoma and superficial malignant melanoma, an 
increase in the density of FXIII-A-positive DCs was associated with a low 
proliferative rate [58]. 
According to studies by our laboratory with the newest marker 
combinations and antibodies, in the various examined skin malignancies, 
FXIII-A-positive cells were almost exclusively tumor-associated macrophages. 
Tumor-associated macrophages are also polarized via the alternative 
pathway fitting into the concept that FXIII-A-positive macrophages are 
associated with tissue remodeling processes, thus being the prime 
pathological features in most of the malignancies. Importantly, FXIII-A-positive 
cells were found in high numbers in close association with fibrin deposits 
around tumor cells suggesting that ecFXIII-A with a possible macrophage 
source might be involved in tumor matrix formation [9, 59]. In line with this 
finding, an interesting study demonstrated that FXIII contributes to 
hematogenous metastasis formation, as the genetic elimination of FXIII-A 
significantly decreased lung metastasis formation in mice. As a possible 
explanation, FXIII was shown to enhance the early survival of embolic tumor 
cells by impeding natural killer cell function and protecting the newly localized 
tumor cells from natural killer cell-mediated lysis where the cross-linked fibrin 
matrices might be crucial [60].  
Taking these data into consideration, to answer in full detail whether 
FXIII-A-positive macrophages support or inhibit tumor growth is an interesting 
topic for future studies. 
 
 
FXIII-A in T-cell dermatoses 
 
FXIII-A-positive cells showed increased numbers in skin samples from 
atopic eczema, psoriasis, lichen planus, spongiotic dermatitis, chronic graft 
versus host disease (GVHD), pityriasis alba and mycosis fungoides. 
Introducing these diseases in more detail is beyond the scope of this review. 
In summary, these inflammatory diseases all have a notable accumulation of 
T cells, which led to the hypothesis that FXIII-A-positive cells might be able to 
cross talk with T cells through their dendrites and could present certain 
antigens. A possible FXIII-A-positive cell – lymphocyte interaction was 
observed in atopic dermatitis at the site of spongiosis and vesicle formation in 
the epidermis, while in psoriatic plaques, an expanding population of FXIII-A-
positive DCs was accompanied by endothelial and T lymphocyte expansion 
[61].  
Deguchi et al. compared the number of antigen-presenting cells in 
atopic dermatitis, psoriasis, lichen planus and GVHD. They found that there 
was only minimal change in the number of CD68+ macrophages in all 
samples compared to healthy skin. However, there was a significant increase 
in the amount of CD1a+, FXIII-A-positive cells in lichen planus, spongiotic 
dermatitis, chronic GVHD, both in the dermis and epidermis. In psoriasis, 
even though the number of FXIII-A-positive cells increased, it did not reach 
statistical significance, and in acute GVHD, there was a significant decrease 
in these cells [62]. In a murine model, Yoo et al. demonstrated that during 
acute GVHD, FXIII-A-positive DCs migrated to the superficial dermis and 
became hypertrophic and highly branched [63]. Additionally, in drug-induced 
toxic epidermal necrolysis (TEN), decreased numbers of FXIII-A-positive DCs 
were detected	  [64]. 
An increased number of FXIII-A-positive DCs were also described in 
pityriasis alba, suggesting that it could mark a subtle inflammation behind the 
postinflammatory hypopigmentation, but other causes besides FXIII 
accumulation were not excluded [65].  
 
 
FXIII-A in sclerotic disorders 
 
Scleroderma, and its localized form, morphea, is characterized by 
fibrosis involving the dermis and the subcutaneous tissue, with prominent 
ECM reorganization. While characterizing the cells involved in the lesions, it 
was found that FXIII-A positivity was lost in the papillary dermis but became 
prominent in the reticular dermis at the site of fibrosis. Interestingly, preceding 
the appearance of intense fibrosis, a reduction was also found in FXIII-A-
positive cell numbers. This finding pointed to the presence of FXIII-A-positive 
cells that varied according to different stages of disease pathogenesis [66], 
and these cells might be important in fibrosis by cross-linking the newly 
formed ECM also found in scleroderma [67].  
Interestingly, in a case of self-healing papular mucinosis, which is a 
milder form of sclerodermoid lichen myxedematosus, CD34+ or FXIII-A-
positive DCs have been described next to mast cells, suggesting that these 
cells together could contribute to the dermal mucin deposition of the lesions 
[68]. 
 
 FXIII-A in wound healing and angiogenesis 
 
Wounding is the most commonly observed pathological condition, 
marked by the presentation of damage-associated molecular patterns (e.g., 
ATP, HSP, HMGB1, hyaluronan fragments, DNA, heparin sulfate, etc.). It can 
be the result of trauma/injury, impaired circulation or necrosis with an 
infectious background. In the complex process of wound healing, cells and 
enzymes work together in a finely tuned system. Wound healing is divided 
into three stages: the inflammatory phase, proliferative phase and maturation 
phase. During the inflammatory phase (1-3 day of wound healing), the clot 
forms, the inflammatory cascade is initiated, and neutrophils and 
macrophages are drawn to the wound site. Around day 4, fibroblasts, vessel 
formation and ECM production overtakes the scenery, and the transition to the 
proliferative phase occurs. From week 3, myofibroblasts, collagen remodeling, 
and wound contraction become characteristic of the maturation phase [69, 
70].  
The strongest piece of evidence supporting the role of FXIII-A in wound 
healing is that 14-36% of patients with FXIII-A deficiency experience impaired 
wound healing and abnormal scar formation [8]. Such impaired wound healing 
was also confirmed by using FXIII-A transgenic mice (deletion of the exon 
encoding the active site cysteine of the mouse FXIII-A). Inbal et al. found 
significant differences in maturity and organization of the wound between the 
controls, the FXIII-A-deficient and the FXIII-A-deficient recombinant FXIII 
(rFXIII)-treated mice. Whereas the controls and the group treated with rFXIII 
had a normal mature wound healing process, the FXIII-A-deficient mice 
without treatment showed delayed re-epithelialization, irregular fibrotic scars 
with ill-defined edges, discoloration and necrotized fissures on histological 
slides [71]. A study of myocardial infarction (MI) in mice showed that FXIII 
correlates with predicted healing time and ventricular wall thickness. 
Nonetheless, in a different study, the association of decreased FXIII levels 
with wall rupture in patients after MI and its beneficial effect in decreasing 
vascular permeability during myocardial ischemia were noted [72-75].	  
 These findings all support the complex roles of FXIII-A and strongly 
suggested that the observed differences were not simply related to the blood 
coagulation defect accounting for the acute, excessive hemorrhage of these 
patients. The most significant observation was that the impaired wound 
healing could be almost completely rescued with rFXIII-A. Therefore, we focus 
on pFXIII-A and ecFXIII-A to address the pathways in which FXIII-A could 
play a role. Nevertheless, it is important to emphasize that FXIII-A expressing 
alternatively activated macrophages [34, 37] are important in the clearance of 
wound debridement, with an increased number of scavenger receptors and 
the binding of apoptotic cells [3, 69, 76].  
After tissue injury, pFXIII is rapidly activated, following platelet 
aggregations and the initiated coagulation cascade. Upon activation by 
thrombin and calcium, activated FXIII-A (FXIII-A2*) binds fibrin polymers 
together to form a mature clot. FXIII-A2* is bound to fibrin and to ECM 
components, such as fibronectin, which is also cross-linked at cellular matrix 
assembly sites [8, 77, 78], incorporating it into the fibrin clot. FXIII-A2* is also 
pivotal in fibroblast adherence and promoting fibroblast migration [79]. 
Moreover, FXIII-A2* interacts with complement C3, integrating it in the fibrin 
clot and with this delaying fibrinolysis [23]. Importantly, FXIII-A2* can cross-
link other matrix components as well as vitronectin, osteopontin, 
thrombospondin, collagen VI and von Willebrand factor, which could further 
impact cell attachment [8]. In addition, FXIII-A2* could mediate endothelial 
cell-platelet interaction through αvβ3-integrin (vitronectin receptor), regardless 
of its transglutaminase activity [80], thus making FXIII-A important in new 
vessel formation and remodeling. Inbal et al. described that the binding of 
FXIII-A2* to endothelial integrin αvβ3 leads to αvβ3-VEGFR-2 cross-linkage and 
a consequent VEGFR-2 activation. VEGFR-2 activation increased cell 
proliferation and survival via multiple pathways by upregulating Erg-1 and 
cJun transcription factors and downregulating thrombospondin-1 (TSP-1) on 
mRNA and protein levels [81]. TSP-1 is an antiangiogenic protein that by 
binding CD36 on the surface of epithelial cells induces their apoptosis. In 
transgenic TSP-1-overexpressing mice, delayed granulation tissue formation 
and delayed wound healing were observed [82]. Importantly, Dadrik et al also 
found that an antibody for αvβ3-integrin (vitronectin receptor) blocked the 
binding of FXIII-A2* to fibroblasts, showing this receptor to be the target of the 
factor also on fibroblasts suggesting its role in the antiapoptotic effect of FXIII 
[83].  
As demonstrated above, FXIII plays a central role in all stages of 
wound healing, whether it is clot formation, extracellular matrix formation, 
macrophage/monocyte activation, enhancement of fibroblast and epithelial 
cell migration, FXIII is an essential part of the pathway. These findings make it 
a promising future treatment option in wound healing, which we will discuss 
later to a fuller extent.  
 
 
Future perspectives for FXIII-A in the field of dermatology 
 
Based on the variety of processes in which FXIII-A is considered to 
have a role (Table 3.), translating basic research into clinical practice is an 
interesting field with potential pathological and therapeutic relevance, which 
we aim to address in the following section.  
 
Understanding FXIII-A-positive cells in skin lesions 
 
Detection of FXIII-A in inflammatory and malignant diseases will 
unquestionably keep its place in dermatological diagnosis. However, more 
data and relevant experiments are needed to answer the long-lasting question 
as to whether FXIII-A is just a marker or also contributes to disease 
pathogenesis. This question is of particular importance in malignancies, 
where answering the level of contribution to the function of tumor-associated 
macrophages is as important as the role of ecFXIII-A in tumor matrix 
remodeling and could give FXIII-A a place in predicting tumor progression.  
More and more data are anticipated regarding the origin, the functional 
properties and the gene expression profiles of FXIII-A-positive cells with the 
improvement of the methods and techniques to work on ex vivo dermal 
immune cells. These techniques may allow us to study them, perhaps even at 
a single-cell level, without affecting their marker profiles and behaviors during 
their isolation and separation, such as antigen presentation. 
 
Wound treatment  
 
Application of FXIII is the most promising in wound management, with 
a potential breakthrough already. Administration of rFXIII has been tested as 
a treatment option in various diseases, such as Crohn’s disease, and in 
microvascular surgeries. During vascular grafting, the addition of rFXIII to the 
fibrin sealant resulted in a more desirable outcome than with the fibrin alone 
[84]. Moreover, topical application of rFXIII on heterotopic neonatal mouse 
heart allografts produced higher numbers of new vessels and increased 
contractility compared to the untreated mice, suggesting that rFXIII could 
potentially have a therapeutic effect in diseases where restoring circulation is 
essential [85]. It could have importance in dermatological diseases such as 
chronic venous and neuropathic ulcers, NL and pyoderma gangrenosum, an 
autoinflammatory disease with severe ulceration. In line with these findings, 
the studies conducted so far on the application of FXIII as a treatment option 
in dermal wound treatment are promising. Accelerated wound surface 
reduction, shorter healing time, improved availability of granulation tissue, and 
decreased secretion and bleeding tendencies were all reported following daily 
local administration of FXIII concentrate on clear, noninfected wounds of 
chronic venous leg ulcers and on pyoderma gangrenosum lesions [24, 86-90].  
However, it should be noted that success is very dependent on the 
selection of the involved subjects. This selection is in regard to the 
background of the wound, other comorbidities and genetic associations. 
These criteria are best reflected in the case of arterial-venous mixed disease 
patients [86] where none of the beneficial effects could be observed, which 
was contrary to chronic venous leg ulcers (CVLU). In CVLU the Val34Leu, 
Tyr204Phe, Pro564Leu polymorphisms of FXIII-A did not shown any relation 
to the prevalence of the ulcer, but Leu34 and Leu564 alleles were associated 
with smaller ulcer size [91-94].  
 
FXIII-A in connective tissue disorders and rejuvenation 
 
The ability of FXIII-A to affect collagen synthesis and ECM remodeling 
is also of potential interest. In particular, FXIII-A was already shown to be 
beneficial in diseases such as scleroderma. After systemic application of 
rFXIII-A, a decrease in stiffness of the skin and improved musculoskeletal 
symptoms were observed. This finding could be related to its possible effect in 
downregulation of collagen synthesis [95]. We also need to mention here that 
elevated pFXIII levels were found to promote inflammation and degenerative 
tissue remodeling in rheumatoid arthritis [96, 97]. This finding should be kept 
in mind and considered in the safety measurements of studies yet to come.  
Platelet-rich plasma (PRP) is widely used for its beneficial effects in 
wound healing and rejuvenation via multiple actions, as it contains several 
different types of molecules such as growth factors and cytokines [98]. Some 
of the results from treatment of chronic wounds with PRP [98-100] are similar 
to those we have discussed in relation to local application of rFXIII in CVLU 
[86]. Thus far, there have been no reports, at least to our knowledge, about 
the FXIII-A content of PRP or its contribution to the effects of PRP. However, 
further investigations are needed based on the complex cellular functions, the 
substrate profile of FXIII-A, and its involvement in the various steps of wound 
healing.  	  	  
 
Abbreviations for factor XIII 
Factor XIII FXIII 
Factor XIII subunit A FXIII-A 
Factor XIII subunit B FXIII-B 
Factor XIII subunit A as a dimer FXIII-A2 
Factor XIII in plasma pFXIII 
Factor XIII in cells cFXIII 
Factor XIII in the extracellular space ecFXIII 
Factor XIII subunit A in plasma as part of the 
tetramer or in dimer form 
pFXIII-A 
Factor XIII subunit A in cells as part of the 
tetramer or in dimer form 
cFXIII-A 
Factor XIII subunit A in the extracellular space 
as part of the tetramer or in dimer form 
ecFXIII-A 
Recombinant factor XIII rFXIII 
Activated factor XIII subunit A FXIII-A2* 
Table 1. Abbreviations of certain forms of factor XIII used in the article 	  
Marker 
Coexpression 
with FXIII+/- 
(%) 
 
In dermatology Function Expressing cells References 
CD11c 
(CR4) 
- Normal skin • type I transmembrane 
glycoprotein, 
• integrin αX (ITGAX) 
forms with ITGB2 a 
leukocyte specific 
integrin receptor (CR4) 
• myeloid 
dendritic cells 
[25, 37, 
101, 102] - NL 
- GA 
- AD 
- Psoriasis 
- Stromal cell cc. 
CD1c 
(BDCA-1) 
- normal skin • type I membrane 
glycoprotein 
• mediates the 
presentation of 
nonpeptide antigens to T 
cells 
• myeloid 
dendritic cells 
[25, 37, 
103] - NL 
- GA 
+ (25%) MF 
+ (25%) Psoriasis 
CD45 
+ Normal skin • protein tyrosine 
phosphatase 
• required for 
differentiation, growth, 
mitosis 
• bone marrow 
derived cells 
[37, 61, 
64, 101] - AD 
- Psoriasis 
HLADR 
+++ (85%) Normal skin • MHC class II receptor 
• antigen presentation to 
T cells 
• antigen 
presenting 
cells 
[37, 48, 
101, 102] + AD 
+ Psoriasis 
- Histiocytosis 
CD34 
- JLS • single chain 
transmembrane 
glycoprotein 
• regulates cell-cell 
adhesion and inhibits 
hematopoietic cell 
differentiation  
• hematopoetic 
progenitor 
cells 
• endothelial 
progenitor 
cells 
• vascular 
endothelial 
[53, 67, 
68, 104, 
105] 
- Self healing papular mucinosis 
- DF 
- DFSP  
- Oral lichen planus 
cells 
CD11b 
(MAC-1α) - Normal skin 
• integrin αM chain 
• part of C3 complement 
receptor 
• receptor for C3bi, 
fibrinogen, FX 
• myeloid cells 
• monocytes 
• NK cells 
(weak) 
[101] 
CD14 + (22%) Normal skin 
• lipopolysaccharide 
receptor 
• monocytes 
• macrophages 
• myeloid 
dendritic cells 
[101, 
102] 
CD83 
- Normal skin • immunoglobulin 
receptor 
• antigen presentation, T 
cell activation 
• mature 
dendritic cells 
[25, 48] 
- NL 
- GA 
  Histiocytosis 
CD205 
(DEC205) - Normal skin 
• C type lecithin type I 
membrane protein, part 
of the macrophage 
mannose receptor 
family 
• participates in antigen 
endocytosis 
• mature 
dendritic cells 
• thymic 
epithelial cells 
• monocytes 
[37] 
CD209 
(ICAM-3, 
DC-SIGN) 
+++ (98.8%) Normal skin 
• C type lecithin receptor 
type II 
• adhesion receptor, 
connection between 
DC-T cells and DC-
endothel, antigen 
receptor  
• tissue 
dendritic cells 
• macrophages  
• immature 
dendritic cells  
[25] 
+++ (96%) NL 
+++ (93.5%) GA 
CD208   
(LAMP-3, 
DC-LAM) 
- Normal skin • type I lysosome associated membrane 
glycoprotein 
• maturation marker 
(upregulated by GM-
CSF, IL-4, TNFα) 
• mature 
dendritic cells 
[25, 37] 
- NL 
 - GA 
CD123 
(IL3Rα 
chain) 
- Normal skin • forms high affinity IL3 
receptor 
• cell growth and 
differentiation 
• plasmacytoid 
dendritic cells 
• basophil 
granulocytes 
[37, 106, 
107] 
- Tuberculoid leprosy 
- Lepromatous leprosy 
CD68 
+++ (85.5%) Normal skin • type I 
lysosomal/endosomal 
associated membrane 
glycoprotein 
• binds low density 
lipoprotein 
• monocytes 
• tissue 
macrophages 
• dendritic cells 
[25, 47, 
48, 52, 
62, 64, 
108] 
++ (64.33%) NL 
++ (62.3%) GA 
- AD 
- Psoriasis 
- Lichen planus 
- Chronic GVHD 
+++ Dermal dendrocytomas 
CD1a 
(Leu-6) 
- Normal skin • type I memerane 
glycoprotein 
• lipid and glycolipid 
• Langerhans 
cells 
• dendritic cells 
[25, 48, 
62, 64, 
101, 103, 
- NL 
- GA 
- AD antigen presentation • cortical 
thymocytes 
106, 107] 
- Psoriasis 
- Lichen planus 
- Chronic GVHD 
- Leprosy 
- LCH/DC histiocytosis 
CD207 
(langerin) 
- 
Tuberculoid 
leprosy 
 
• type II C-type 
transmembrane lecithin 
receptor 
• captures antigens and 
induces Birbeck granule 
formation 
• Langerhans 
cells 
• dendritic cells 
[48, 106] 
- LCH 
CD36 +++ (92%) Normal skin 
• class B scavenger 
receptor 
• binds long chain fatty 
acids, oxidized LDL, 
collagen type I, IV and 
V and thrombospondin, 
as well as for apoptotic 
cells 
 
• endothelial 
cells 
• erythrocytes 
• platelets 
• monocytes 
• macrophages 
• macrophage-
derived 
dendritic cells 
 
[101] 
CD54 
(ICAM-1) 
- Normal skin 
• type I transmembrane 
glycoprotein 
• adhesion molecule, 
ligand for integrin 
• monocytes 
• macrophages 
• lymphocytes 
• activated 
endothelial 
cells 
• granulocytes 
• dendritic cells 
[101, 
105] 
+ Lichen planus 
CD163 
(M130) 
+++(97.8%) Normal skin 
• single chain 
transmembrane protein, 
hemoglobin/haptoglobin 
complex scavenger 
receptor, 
• signal transduction for 
proinflammatory 
cytokine production 
• mature tissue 
macrophage 
• blood 
monocyte 
[17, 25, 
37] 
+++(77.1%) NL 
+++(85.5%) GA 
CD206 
(MMR) 
+++ (94.8%) Normal skin 
• type I membrane 
protein, macrophage 
mannose receptor 
• mediates antigen 
endocytosis/ 
phagocytosis 
• macrophages 
• dendritic cells 
• endothelial 
cells 
[25] 
++(52.2%) NL 
++ (74.7%) GA 
S100 
- 
LHC/DC 
histiocytosis 
 
• Ca2+ binding protein 
regulation of protein 
phosphorylation, 
transcription factors 
• Ca2+ homeostasis, the 
dynamics of 
cytoskeleton 
constituents, enzyme 
activities, cell growth 
and differentiation, and 
(Neural crest cells) 
• Langerhans 
cells  
• dendritic cells 
• macrophages 
• kerationcytes 
• adipocytes 
• myoepithel 
• chondrocytes 
[47, 48, 
53, 55, 
104, 109] 
- Chromoblasto-mycosis 
- DF 
- DFSP 
+? Neurofibroma the inflammatory 
response - Schwannoma 
Table 2. Markers used most often during immunohistochemistry to distinguish 
cells in the dermis and epidermis and their co-expression with FXIII in normal 
skin and dermatological conditions (NL=necrobiosis lipoidica, GA=granuloma 
annulare, AD= atopic dermatitis, GVHD= graft versus host disease, DF= dermatofibroma, 
DFSP=dermatofibrosarcoma protuberans, LHC=Langerhans cells histiocytosis, DC=dendritic 
cell, JLS= juvenile localized scleroderma, − < 20% expression, 20%<+<50%, 50%<++<75% 
expression, +++>75% expression) 	  	  	  
                                 Affected cells by factor XIII 
ECM monocytes macrophages dendritic 
cells 
fibroblasts endothelial 
cells 
Mechanism of action 
- crosslinking 
ECM 
components 
and 
complement C3 
- crosslinking 
bacterial 
surface 
components 
- fibrin matrix 
formation 
around tumor 
cells  
- inducing 
tumor cell exit 
to the 
vasculature 
- dimerization of 
AT1 and 
mobilization of 
cells 
- facilitating 
entry into the 
artery wall 
- inducing 
receptor 
mediated 
phagocytosis  
- antiapoptotic 
- promoting 
proliferation 
migration 
- translocation to 
the nucleus and 
macrophage 
activation 
- gene expression 
regulation 
- released 
cFXIIIA by 
damaged 
macrophages  
- induction of 
antigen 
presentation 
- induction of 
cytokine 
production 
- induction of 
mucin 
deposition 
- enhancing 
adherence and 
migration 
- antiapoptotic 
- promoting 
proliferation 
migration 
- homeostasis of 
collagen 
production 
- endothel-platelet 
interaction 
- antiapoptotic 
- promoting 
proliferation and 
migration 
 References [1,	  8-­‐10,	  23]	   [1,	  8-­‐10,	  23]	   [1,	  8-­‐10,	  23,	  25,	  37,	  43,	  102]	  	   [1,	  8-­‐10,	  23],	  62, 63, 
65, 66, 68-
72]	  	  
[1,	  5,	  8-­‐10,	  23]	   [1,	  8-­‐10,	  23]	  
Table 3. Previously described/suggested mechanisms of action related to skin 
homeostasis and diseases (ECM= extracellular matrix) 
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